144 related articles for article (PubMed ID: 11986346)
21. Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB.
Eliseev RA; Schwarz EM; Zuscik MJ; O'Keefe RJ; Drissi H; Rosier RN
Exp Cell Res; 2006 Jan; 312(1):40-50. PubMed ID: 16259979
[TBL] [Abstract][Full Text] [Related]
22. Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions.
Kloen P; Lauzier D; Hamdy RC
Bone; 2012 Jul; 51(1):59-68. PubMed ID: 22521262
[TBL] [Abstract][Full Text] [Related]
23. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer.
Bobinac D; Marić I; Zoricić S; Spanjol J; Dordević G; Mustać E; Fuckar Z
Croat Med J; 2005 Jun; 46(3):389-96. PubMed ID: 15861517
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
[TBL] [Abstract][Full Text] [Related]
25. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
26. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.
Sulzbacher I; Birner P; Trieb K; Lang S; Chott A
Virchows Arch; 2002 Oct; 441(4):345-9. PubMed ID: 12404059
[TBL] [Abstract][Full Text] [Related]
27. Measurement of total and local bone morphogenetic protein concentration in bone tumours.
Laitinen M; Jortikka L; Halttunen T; Nevalainen J; Aho AJ; Marttinen A; Lindholm TS
Int Orthop; 1997; 21(3):188-93. PubMed ID: 9266301
[TBL] [Abstract][Full Text] [Related]
28. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma.
Bago-Horvath Z; Schmid K; Rössler F; Nagy-Bojarszky K; Funovics P; Sulzbacher I
Pathology; 2014 Aug; 46(5):411-5. PubMed ID: 24842377
[TBL] [Abstract][Full Text] [Related]
29. Bone morphogenetic proteins are expressed by both bone-forming and non-bone-forming lesions.
Khurana JS; Ogino S; Shen T; Parekh H; Scherbel U; DeLong W; Feldman MD; Zhang PJ; Wolfe HJ; Alman BA
Arch Pathol Lab Med; 2004 Nov; 128(11):1267-69. PubMed ID: 15508192
[TBL] [Abstract][Full Text] [Related]
30. Autogenous regulation of a network of bone morphogenetic proteins (BMPs) mediates the osteogenic differentiation in murine marrow stromal cells.
Edgar CM; Chakravarthy V; Barnes G; Kakar S; Gerstenfeld LC; Einhorn TA
Bone; 2007 May; 40(5):1389-98. PubMed ID: 17303481
[TBL] [Abstract][Full Text] [Related]
31. Expression of bone morphogenetic proteins (BMPs), their receptors, and activins in normal and scarred conjunctiva: role of BMP-6 and activin-A in conjunctival scarring?
Andreev K; Zenkel M; Kruse F; Jünemann A; Schlötzer-Schrehardt U
Exp Eye Res; 2006 Nov; 83(5):1162-70. PubMed ID: 16879818
[TBL] [Abstract][Full Text] [Related]
32. A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.
Masrouha KZ; Khattab R; Tawil A; Abdallah A; Saghieh S; Haidar R; Abboud M; Khoury NJ
J Bone Joint Surg Br; 2012 Mar; 94(3):419-24. PubMed ID: 22371553
[TBL] [Abstract][Full Text] [Related]
33. [Radioimmunoimaging of osteosarcoma with BMP monoclonal antibodies].
Wang Z
Zhonghua Wai Ke Za Zhi; 1991 Aug; 29(8):489-91, 525. PubMed ID: 1813243
[TBL] [Abstract][Full Text] [Related]
34. Nrf2 expression is associated with poor outcome in osteosarcoma.
Park JY; Kim YW; Park YK
Pathology; 2012 Dec; 44(7):617-21. PubMed ID: 23172081
[TBL] [Abstract][Full Text] [Related]
35. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher I; Birner P; Trieb K; Träxler M; Lang S; Chott A
Mod Pathol; 2003 Jan; 16(1):66-71. PubMed ID: 12527715
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.
Shnyder SD; Hayes AJ; Pringle J; Archer CW
Br J Cancer; 1998 Sep; 78(6):757-9. PubMed ID: 9743295
[TBL] [Abstract][Full Text] [Related]
37. Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma.
Zhu Y; Zhou J; Ji Y; Yu B
Mol Med Rep; 2014 Aug; 10(2):737-42. PubMed ID: 24919955
[TBL] [Abstract][Full Text] [Related]
38. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
[TBL] [Abstract][Full Text] [Related]
39. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
